Abstract
Background: The inherent plasticity of tumor cells provides a mechanism of resistance to molecularly targeted therapies, exemplified by adeno-to-neuroendocrine lineage transitions in prostate and lung cancer. Here we investigate the root cause of lineage plasticity following Trp53 and Rb1 loss in genetically engineered mouse models, murine and patient-derived organoid cultures, and patient biospecimens with castrate-resistant prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
